Enbrel (etanercept) is a prescription biologic medication used to treat several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It works by blocking a specific protein in the immune system that drives inflammation, and it’s approved for both adults and certain pediatric patients. Here’s what you should know about each condition it treats, how it works, and what to expect.
Conditions Enbrel Treats in Adults
Enbrel is FDA-approved for four conditions in adults, all of which involve the immune system attacking the body’s own tissues.
Rheumatoid arthritis (RA) is the most well-known use. RA causes chronic joint pain, swelling, and stiffness as the immune system attacks the lining of the joints. In clinical trials, about 59% to 72% of patients taking Enbrel achieved at least a 20% improvement in symptoms by six months, compared to just 11% to 27% on placebo. Around 40% saw their symptoms cut in half. Enbrel can be used alone or combined with methotrexate for RA.
Psoriatic arthritis (PsA) combines the joint inflammation of arthritis with the skin symptoms of psoriasis. Enbrel treats both the joint and skin components. In trials, patients noticed improvement as early as four weeks, and those benefits held steady through at least six months of treatment.
Ankylosing spondylitis (AS) primarily affects the spine, causing pain and stiffness in the lower back and hips that tends to be worst in the morning or after periods of inactivity. Over time, it can fuse vertebrae together. Enbrel helps reduce that inflammation and preserve mobility.
Plaque psoriasis (PsO) is the skin condition that produces thick, red, scaly patches. Enbrel is approved for moderate to severe cases in adults who are candidates for systemic therapy. In one trial, 30% of patients achieved 75% skin clearance after 12 weeks, rising to 56% after 24 weeks. The median time to see significant improvement was about one to two months.
Approved Uses in Children
Enbrel is one of the few biologics with pediatric approvals for multiple conditions. It’s approved for polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis in children aged 2 and older, and for plaque psoriasis in children aged 4 and older. Dosing for children under about 138 pounds is weight-based at 0.8 mg per kilogram weekly, while children at or above that weight receive the standard adult dose of 50 mg weekly.
How Enbrel Works
In inflammatory diseases like RA and psoriasis, the immune system overproduces a signaling protein called tumor necrosis factor (TNF). TNF is a normal part of immune defense, but when there’s too much of it, it triggers chronic inflammation that damages joints, skin, and other tissues.
Enbrel is a lab-made protein designed to act like a decoy receptor. It mimics the natural TNF receptor on cell surfaces, binding to TNF molecules before they can attach to real receptors and trigger inflammation. Think of it as a sponge that soaks up excess TNF circulating in your body. This is different from some other TNF blockers (like infliximab) that use antibodies to latch onto TNF. Enbrel’s structure means it binds one TNF molecule at a time rather than forming large clusters, which gives it a somewhat different safety and effectiveness profile compared to other drugs in the same class.
What Treatment Looks Like
Enbrel is a subcutaneous injection, meaning it goes just under the skin rather than into a vein. Most people give themselves the injection at home using a prefilled syringe or autoinjector pen. For RA, psoriatic arthritis, and ankylosing spondylitis, the standard adult dose is 50 mg once a week. Plaque psoriasis starts at a higher frequency: 50 mg twice weekly for the first three months, then drops to once weekly.
Improvement tends to come relatively quickly for a biologic. In rheumatoid arthritis, most patients notice some relief within one to two weeks, and nearly all responders see results by three months. For psoriasis, meaningful skin clearance typically begins within one to two months. If you haven’t seen any improvement after three to four months, your prescriber will likely reassess whether Enbrel is the right fit.
Important Safety Considerations
Enbrel carries a boxed warning, the FDA’s most serious safety label, for two risks: serious infections and malignancies.
Because Enbrel suppresses part of the immune system, it increases the risk of infections that can become severe enough to require hospitalization. These include tuberculosis (including reactivation of a latent infection you may not know you have), certain fungal infections, and bacterial infections from organisms like Legionella and Listeria. Before starting Enbrel, you’ll be tested for latent tuberculosis and treated for it if the test is positive. If you develop a serious infection while on Enbrel, treatment is stopped.
The malignancy warning notes that lymphoma and other cancers, some fatal, have been reported in children and adolescents taking TNF blockers including Enbrel. The overall cancer risk in adults is less clear, but it’s something prescribers weigh against the benefits of treatment, particularly for patients with a history of cancer.
You should not receive live vaccines while taking Enbrel, since the drug’s effect on the immune system could allow a live vaccine virus to cause an actual infection rather than just building immunity. Inactivated vaccines (like the flu shot) are generally fine and often recommended.
Common Side Effects
The most frequently reported side effect is a reaction at the injection site: redness, swelling, itching, or pain where the needle went in. These reactions are usually mild, tend to occur more often in the first month of treatment, and typically become less bothersome over time. Upper respiratory infections (common colds and sinus infections) are also reported more often in people taking Enbrel than in those on placebo, which makes sense given the drug’s immune-suppressing effects. Headaches and nausea occur in some patients but are generally not severe enough to stop treatment.
Biosimilar Options
Several biosimilar versions of Enbrel have received FDA approval. Biosimilars are near-identical copies of biologic drugs that typically cost less than the original. The availability and pricing of specific biosimilars can change, so if cost is a concern, it’s worth asking your pharmacist or prescriber whether a biosimilar is available and covered by your insurance. Biosimilars go through rigorous testing to confirm they work the same way and carry the same safety profile as the original drug.